# Phase 1/2 Lupus Erythematosus, Systemic trials: 29 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials in phase 1/2 for Lupus Erythematosus, Systemic that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Lupus Erythematosus, Systemic trials: 29 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/lupus-erythematosus-systemic

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 29
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946367 | Dual-targeting of B & T Cell Pathways Evaluation Trial | Diabetes Free, Inc. | Phase 1/2 | Recruiting | Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Idiopathic Inflammatory... | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946367) |
| September 2, 2026 | NCT07800871 | FT839 in Autoimmune Diseases | Fate Therapeutics | Phase 1/2 | Recruiting | ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA), Systemic Lupus... | 446 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07800871) |
| September 2, 2026 | NCT07799116 | Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Phase 1/2 | Recruiting | Lupus Nephritis, Lupus Nephritis (LN) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07799116) |
| August 24, 2026 | NCT07782450 | A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases | Pfizer | Phase 1/2 | Not yet recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myositis, Systemic Sclerosis | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782450) |
| August 21, 2026 | NCT07778446 | A Study to Test CRT-402 in Refractory Autoimmune Disease | Myeloid Therapeutics | Phase 1/2 | Recruiting | Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Scleroderma, Myositis | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778446) |
| June 22, 2026 | NCT07659704 | CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus | University of Sao Paulo | Phase 1/2 | Not yet recruiting | Lupus Erythematosus, Systemic | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07659704) |
| April 20, 2026 | NCT07538154 | A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus | Sinocelltech Ltd. | Phase 1/2 | Not yet recruiting | Systemic Lupus Erythematosus (SLE) | 159 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07538154) |
| April 13, 2026 | NCT07523542 | SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus | Beijing Biotech | Phase 1/2 | Recruiting | REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523542) |
| January 23, 2026 | NCT07364396 | Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus | Curocell Inc. | Phase 1/2 | Not yet recruiting | Lupus Nephritis, Lupus Nephritis (LN), SLE, SLE (Systemic Lupus) | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07364396) |
| January 16, 2026 | NCT07348055 | A Study of GR1803 in Systemic Lupus Erythematosus | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Systemic Lupus Erthematosus, Auto Immune Disease | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07348055) |
| September 22, 2025 | NCT07185269 | The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1/2 | Recruiting | Systemic Lupus Erythematosus (SLE) | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07185269) |
| June 27, 2025 | NCT07041801 | Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells | Shenzhen Beike Bio-Technology Co., Ltd. | Phase 1/2 | Recruiting | Systemic Lupus Erythematosus (SLE) | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07041801) |
| June 8, 2025 | NCT07010835 | Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus | Excyte Biopharma Ltd | Phase 1/2 | Recruiting | Systemic Lupus Erythematosus (SLE) | 189 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07010835) |
| March 27, 2025 | NCT06897930 | A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE | AstraZeneca | Phase 1/2 | Recruiting | Lupus Erythematosus, Systemic | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06897930) |
| February 21, 2025 | NCT06841042 | A Study of SCTB35 in Patients with Systemic Lupus Erythematosus | Sinocelltech Ltd. | Phase 1/2 | Recruiting | System Lupus Erythematosus | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06841042) |
| February 21, 2025 | NCT06839976 | CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus | Children's Hospital of Philadelphia | Phase 1/2 | Recruiting | SLE, Systemic Lupus Erythematosus (SLE), CAR T Cell, CART19, Cell Therapy, Lupus, Lupus Nephritis (LN) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06839976) |
| November 12, 2024 | NCT06685042 | Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 1/2 | Recruiting | Lupus Erythematosus, Systemic, System; Sclerosis, ANCA Associated Vasculitis, Dermatomyositis, Polymyositis | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06685042) |
| November 5, 2024 | NCT06675422 | JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE) | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Phase 1/2 | Recruiting | Systemic Lupus Erythematosus (SLE) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06675422) |
| October 3, 2024 | NCT06625671 | A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants | DualityBio Inc. | Phase 1/2 | Recruiting | Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06625671) |
| September 5, 2024 | NCT06585514 | Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus | Beijing GoBroad Hospital | Phase 1/2 | Recruiting | Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06585514) |
| August 2, 2024 | NCT06535412 | A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | Phase 1/2 | Recruiting | Systemic Lupus Erythematosus | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06535412) |
| May 30, 2024 | NCT06434363 | Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders | M.D. Anderson Cancer Center | Phase 1/2 | Recruiting | Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus, Lupus Nephritis | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06434363) |
| May 24, 2024 | NCT06428188 | Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases | Essen Biotech | Phase 1/2 | Recruiting | Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus Acute, Sjogren's Syndrome | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06428188) |
| April 4, 2024 | NCT06347718 | CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease | Miltenyi Biomedicine GmbH | Phase 1/2 | Recruiting | Systemic Lupus Erythematosus, Systemic Sclerosis, Dermatomyositis, Polymyositis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06347718) |
| January 3, 2024 | NCT06189157 | MB-CART19.1 in Refractory SLE | Miltenyi Biomedicine GmbH | Phase 1/2 | Recruiting | SLE - Systemic Lupus Erythematosus | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06189157) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Miltenyi Biomedicine GmbH](https://specstream.ai/data/clinical-trials/company/miltenyi-biomedicine-gmbh) | 2 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2 |
| [Sinocelltech Ltd.](https://specstream.ai/data/clinical-trials/company/sinocelltech-ltd) | 2 |
| 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| Excyte Biopharma Ltd | 1 |
| Beijing GoBroad Hospital | 1 |
| DualityBio Inc. | 1 |
| Shenzhen Beike Bio-Technology Co., Ltd. | 1 |
| [Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sunshine-guojian-pharmaceutical-shanghai-co-ltd) | 1 |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 1 |
| [Fate Therapeutics](https://specstream.ai/data/clinical-trials/company/fate-therapeutics) | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Curocell Inc. | 1 |
| Diabetes Free, Inc. | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
| Myeloid Therapeutics | 1 |
| M.D. Anderson Cancer Center | 1 |
| Essen Biotech | 1 |
| University of Sao Paulo | 1 |
| ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | 1 |
| [Genrix (Shanghai) Biopharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/genrix-shanghai-biopharmaceutical-co-ltd) | 1 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 1 |
| Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 1 |
| Children's Hospital of Philadelphia | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 12 |
| United States | 7 |
| Germany | 3 |
| Australia | 3 |
| Canada | 2 |
| Spain | 2 |
| United Kingdom | 1 |
| Brazil | 1 |
| Italy | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Crane services in the United States](https://specstream.ai/data/businesses/crane-services/united-states)
- [Puerto Rican restaurants in the United States](https://specstream.ai/data/businesses/puerto-rican-restaurants/united-states)
- [Disability law firms in the United States](https://specstream.ai/data/businesses/disability-law-firms/united-states)
- [Rheumatology practices in the United States](https://specstream.ai/data/businesses/rheumatology-practices/united-states)
- [Education services in the United States](https://specstream.ai/data/businesses/education-services/united-states)
- [Shared office spaces in the United States](https://specstream.ai/data/businesses/shared-office-spaces/united-states)
